Lancet HIV

Article	Citations
Argentina updates HIV laws	292
Evidence supports use of on-demand PrEP for HIV prevention	151
Transplant donation without discrimination	139
How do we prevent anal cancer in people living with HIV?	138
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-huma	111
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia	110
How much could long-acting PrEP cost in South Africa?	109
Correction to Lancet HIV 2022; 9: e791–800	109
The Australian AIDS crisis through the eyes of volunteers	101
HIV and COVID-19: juxtaposition of two pandemics	97
Optimising anal cancer screening through risk stratification	91
A moment of reckoning	86
Lenacapavir: an attractive option, but proceed with caution	83
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c	82
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial	78
Lung cancer in people living with HIV	77
Controversial chronicler of LGBTQ rights	74
Risk estimation in HIV reveals our usual blind spots	74
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?	66
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	64
Are we ready for long-acting HIV treatment for adolescents?	59
Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trial	57
Unheard testimony	56
Steps toward quick and equitable roll-out of lenacapavir	56
Game-changing study of second-line HIV treatment	55

Gains and gaps: addressing HIV in diverse sex worker groups	53
All roads lead to Westminster: the infected blood scandal	52
Fate of people with HIV in jeopardy in Ukraine	51
Redefining care: injectable HIV treatment for adolescents	51
Making America unhealthy again	50
The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries	49
Equitable access to long-acting PrEP on the way?	48
Suicide prevention research is crucial to achieving health equity for people with HIV	48
Recent gay Black history in the UK	46
Sex as a biological variable in HIV-1 and schistosome co-infection	45
Reducing HIV transmission in British Columbia, Canada	45
Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial	45
WHO recommends lenacapavir for HIV prevention	45
A public health approach to drug use crucial to ending AIDS	44
Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis	42
More evidence for worse COVID-19 outcomes in people with HIV	42
HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study	42
Integration of sexual health and HIV services	42
Stigma reduction is key to improving the HIV care continuum	42
Lateral flow assay-based CD4 cell count testing for advanced HIV disease	41
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor ther	40
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi	40
HIV care cascade and associated factors among men who have sex with men, transgender women, and genderqueer individuals in Zimbabwe: findings from a biobehavioural survey using respondent-driven sampl	38
Use of WHO paediatric weight-band dosing in drug labels	37
PEPFAR: promises and pitfalls	37
Dolutegravir in neonates: finally we are getting there!	37
An eventful conference	37
Eliminating HIV in the UK among men who have sex with men	36
Connie Norman: a warm tribute to a forgotten AIDS activist	36
HIV self-testing: from availability to strategic deployment	34
Patterns of post-partum HIV care engagement	34
How can Africa sustain its HIV response amid US aid cuts?	34
Moving beyond hotspots of HIV prevalence to geospatial hotspots of UNAIDS 95-95-95 targets in sub-Saharan Africa	33
HIV incidence and impact of interventions among female sex workers and their clients in the Middle East and north Africa: a modelling study	33
Preventing sexually transmitted infections in the age of PrEP	33
Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B	33
Living with COVID-19 and preparing for future pandemics: revisiting lessons from the HIV pandemic	32
Advancing the prevention and treatment of HIV in children: priorities for research and development	32
Lesotho's progress towards UNAIDS 95-95-95 targets from 2016 to 2020: comparison of Population-based HIV Impact Assessments	32
The impact of cuts in the US President's Emergency Plan for AIDS Relief funding for HIV pre-exposure prophylaxis in sub-Saharan Africa: a modelling study	32
Lifestyle modification programme for people living with HIV with metabolic dysfunction-associated steatotic liver disease: a randomised controlled trial	32
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and th	31
Trends in HIV testing, the treatment cascade, and HIV incidence among men who have sex with men in Africa: a systematic review and meta-analysis	31
Reduction in mortality from HIV-related CNS infections in routine care in Africa (DREAMM): a before-and-after, implementation study	31
HIV-free generation within reach for Botswana	30
Thank you to The Lancet HIV's statistical and peer reviewers in 2023	30
Reduction of HIV reservoir after stem cell transplantation	30
Highlights from the 25th International AIDS Conference	29
Can treatment-as-prevention and PrEP reduce HIV incidence?	29
Implementation of PrEP in Latin America	26

Effects of self-testing on HIV outcomes in west Africa	26
Coffee with IAS President Beatriz Grinsztejn	25
Second-line HIV treatments for adults in LMICs	25
Addressing partner violence to end infant HIV infection	24
Effects of clinical, comorbid, and social determinants of health on brain ageing in people with and without HIV: a retrospective case-control study	24
Crucial need for improved pharmacovigilance in pregnancy	24
Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study	23
Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa	23
Optimised second-line regimens in the public health approach	22
Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label,	22
Intersectional climate justice, health equity, and HIV	22
Metabolic implications and safety of dolutegravir use in pregnancy	21
A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial	21
No woman left behind: achieving cervical cancer elimination among women living with HIV	21
The HIV care continuum for sexually active transgender women in three metropolitan municipalities in South Africa: findings from a biobehavioural survey 2018–19	20
Closing the gap to UNAIDS 95-95-95: Lesotho's success story	20
Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions	20
Correction to Lancet HIV 2025; 12: e691–700	20
Estimates of the prevalence of undiagnosed HIV among children living with HIV in Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe from 2015 to 2017: an analysis of data from the cros	20
Need for clear inclusion criteria in reviews of antiretroviral treatments	19
Can COVID-19 changes reduce stigma in African HIV clinics?	19
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study	19
Breast cancer survival in women living with HIV	19
Point-of-care testing to achieve paediatric 95-95-95 targets	18
Treatment of HIV and HBV coinfection	18
Complex response to HIV and tuberculosis in South Sudan	18
A field of possibilities for paediatric HIV	17
Integrase inhibitors hand us a new HIV clinical puzzle	17
The HIV vaccine quest: ethical and implementation challenges	17
Identifying risk factors for anal cancer in people with HIV in Spain: a multicentre retrospective cohort study nested in the PISCIS cohort	17
Dolutegravir drug-resistance monitoring in Africa	17
Making PrEP easy	17
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex w	17
Adolescent retention in HIV care within differentiated service-delivery models in sub-Saharan Africa	17
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	17
Realising long-acting ART as first-line treatment	16
Thank you to The Lancet HIV's clinical and statistical peer reviewers in 2021	16
Long-acting PrEP for adolescent girls and young women	16
A new index to guide global drug policies	16
The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities	16
HIV treatment in Russia on the brink of crisis	16
Unified health surveys for integrated health systems	16
HERO—providing support for those engaged in chemsex	16
Trends in suicide mortality among people with HIV after diagnosis during 2012–18: a retrospective, national cohort study in China	16
Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008–20: a national cohort study	16
Initiation and continued use of oral pre-exposure prophylaxis among pregnant and postpartum women in South Africa (PrEP-PP): a demonstration cohort study	15
Non-communicable diseases in older people living with HIV in four African countries: a cohort study	15
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis	15
Activists step in to deliver PEP and PrEP in Mexico	15
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study	15
Critical illness due to infection in people living with HIV	14
Inherited fear: 40 years of HIV/AIDS in the UK	14
HIV-related CNS infections: translating DREAMM into reality	14
Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study	14
Improving outcomes for children in families with HIV	14
Zvandiri—when medicines alone are not enough	14
Ending HIV in Chicago by 2030	14
Expanding options of child-friendly, single-tablet regimens for young children with HIV	13
PEPFAR reauthorisation hangs in the balance	13
HIV viral suppression is key to healthy longevity	13
A career dedicated to public service	13
Correction to Lancet HIV 2025; 12: e473–84	13
Correction to Lancet HIV 2023; 10: e424–26	13
Forgiveness of an intermittent HIV treatment strategy	13
Immunological and virological findings in a patient with exceptional post-treatment control: a case report	13
Trauma-informed HIV prevention for forcibly displaced adolescents and young adults	13
Tajikistan faces a crucial moment in HIV/AIDS response	13
A research framework to support re-engagement and continuous engagement in HIV care	13
HIV incidence estimation among female sex workers in South Africa: a multiple methods analysis of cross-sectional survey data	12
Increased risk of mental illness in people with HIV	12
Long-acting PrEP: new opportunities with some drawbacks	12
Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration	12
Expanding PrEP treatment options with a potent anti-HIV antibody	12
Where does doravirine fit in current antiretroviral therapy?	12
Reimagining HIV prevention with artificial intelligence	12
Equitable access to PrEP is essential to reap its benefits	12
Thank you to The Lancet HIV's statistical and peer reviewers in 2022	12
Home delivery of ART: could this be a reality in South Africa?	11
Screening for chlamydia and incidence of symptomatic infections	11
Putting people first in communication about HIV	11

Real-world safety of pre-exposure prophylaxis for HIV	11
Reassessing oral lead-in for injectable long-acting HIV therapy	11
COVID-19 antivirals must not affect HIV drug supply	11
UK and US militaries update HIV policies	11
Potential population-level effects of HIV self-test distribution among key populations in Côte d'Ivoire, Mali, and Senegal: a mathematical modelling analysis	11
Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004–18: a cohort study	11
Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort	10
Defining principles for a choice-based approach to HIV prevention	10
Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the HPTN 071 [PopART] trial): a modelling study	10
Mexican perspective on the Mosaico HIV vaccine trial	10
Paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharm	10
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-	10
What future for HIV vaccines?	10
Expansion of PrEP and PEP services in China	9
Association of life-course events with predictors of HIV risk behaviour and HIV acquisition in Manicaland, Zimbabwe: a longitudinal analysis of a population cohort	9
Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies	9
Response to Thailand's commitment to support community-led HIV services	9
COP27 Climate Change Conference: urgent action needed for Africa and the world	9
Legislation threat to services for LGBTQ+ people in Georgia	9
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial	9
Low-cost point-of-care urine test to enhance PrEP adherence	9
The urgent need for opioid agonist treatment in Russia	9
Ending AIDS as a public health threat: the imperative for clear messaging on U=U, viral suppression, and zero risk	9
Due south: navigating volatile health research landscapes	8
Understanding and managing disordered sleep in people with HIV	8
Artificial intelligence in HIV research, policy, and clinical care	8
Acceptability, feasibility, and effectiveness of caregiver-assisted HIV self-testing among children using an oral mucosal test in Uganda and Zambia: a prospective interventional study	8
Do we need routine integrase resistance testing before starting antiretroviral therapy?	8
Dolutegravir dosing with rifampicin	8
Elton John AIDS Foundation plugging gaps in HIV funding	8
Immunology of infants who are HIV-exposed uninfected in the parental combination antiretroviral therapy era	8
CD4 cell counts at HIV diagnosis in the Eastern Mediterranean Region	8
Mental health needs of adolescents with HIV in Africa	8
A community-based child health and parenting intervention to improve child HIV testing, health, and development in rural Lesotho (Early Morning Star): a cluster-randomised, controlled trial	8
Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level p	8
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administere	8
HIV epidemiology in the WHO Eastern Mediterranean region: a multicountry programme review	8